| name | es-cushing-testing-for-recurrence-lifelong-except-low-ct-density |
| description | This skill recommends lifelong biochemical testing for recurrence in all patients with Cushing's syndrome after adrenalectomy, except those with resected adrenal adenoma showing CT density <10 Hounsfield units. Use when determining long‑term follow‑up strategy for a post‑adrenalectomy CS patient; triggers include “post‑adrenalectomy Cushing’s syndrome”, “CT density <10 HU”, and “adrenal adenoma resection”. |
Testing for Recurrence Throughout Life Except in Patients Who Underwent Resection of Adrenal Adenoma with CT Density <10 Hounsfield Units
STEP 1 — Gather Information
Collect operative report, pathology confirming adrenal adenoma, non‑contrast CT Hounsfield units of the resected lesion, postoperative biochemical remission status (morning cortisol <5 µg/dL and normal late‑night salivary cortisol or urine free cortisol), and baseline comorbidity assessment. Then proceed to assess the CT density threshold.
STEP 2 — Rule In / Rule Out
If the resected adrenal adenoma has a CT density <10 HU and pathology confirms a benign adenoma, rule out the need for lifelong biochemical recurrence testing; otherwise rule in the need for lifelong testing. End decision: skip lifelong testing for low‑density adenoma or move to classification for all others.
STEP 3 — Classify or Stratify
For patients ruled in for lifelong testing, confirm postoperative eucortisolism (morning cortisol <5 µg/dL and normal late‑night salivary cortisol). If eucortisolism is confirmed, proceed to schedule surveillance; if not, manage persistent hypercortisolism per guideline. End decision: confirm remission status to direct surveillance or treat persistent disease.
STEP 4 — Decide
For patients with confirmed eucortisolism, schedule late‑night salivary cortisol or urine free cortisol every 6–12 months indefinitely and continue routine comorbidity monitoring; for patients with persistent hypercortisolism, initiate appropriate treatment (medical, surgical, or radiation) according to the guideline. End decision: implement lifelong surveillance plan or active treatment.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on symptoms alone to exclude recurrence; ensure CT measurement is performed on non‑contrast scans and that the value truly reflects the adenoma (avoid confusing hyperplasia or carcinoma). A single normal test does not guarantee permanent cure; lifelong periodic testing is required unless the low‑density adenoma criterion is met. Misclassifying an adrenal carcinoma as an adenoma with low CT density can lead to inadequate follow‑up.
Concrete Clinical Example
A 48‑year‑old woman underwent left adrenalectomy for a 2.5 cm adenoma; postoperative pathology showed benign adenoma, non‑contrast CT density was 8 HU, and morning cortisol and late‑night salivary cortisol were normal. According to this skill, she does not require lifelong biochemical testing for Cushing’s recurrence, only standard monitoring of hypertension, diabetes, and osteoporosis.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, https://doi.org/10.1210/jc.2015-1818
TODO: consider adding scripts/calc.py for the es-cushing-testing-for-recurrence-lifelong-except-low-ct-density calculator
